We observed 14.3% of patients to have HER2-positive cancers according to study criteria, which is consistent with other series and may inform future trial design.10,11 Central testing of ERBB/HER2 status was felt to be necessary owing to the special laboratory requirements for HER2 testing in gastroesophageal cancer, which were not available in many UK centers at the time of study design. The gene discussed is EGFR; the disease is cancer.